ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer
Cancer Science · 2024
DOI: 10.1111/cas.16175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Yoshiki Shinomiya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Dexamethasone, Drug Resistance, Neoplasm, Gemcitabine. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis. Neoadjuvant chemotherapy is an effective PDAC treatment option, but chemotherapy causes unfavorable side effects. Glucocorticoids (e.g., dexamethasone [DEX]) are administered to reduce side effects of chemotherapy for solid tumors, including pancreatic cancer. Glucocorticoids have both beneficial and detrimental effects, however. We investigated the functional changes and gene‐expression profile alterations induced by DEX in PDAC cells. PDAC cells were treated with DEX, and the cell proliferation, migration, invasion, and chemosensitivity to gemcitabine (GEM) were evaluated. The results demonstrated decreased cell proliferative capacity, increased cell migration and invasion, and decreased sensitivity to GEM. A comprehensive genetic analysis revealed marked increases in ECM1 and KRT6A in DEX‐treated PDAC cells. We evaluated the effects of ECM1 and KRT6A expression by using PDAC cells transfected with those genes. Neither ECM1 nor KRT6A changed the cells’ proliferation, but each enhanced cell migration and invasion. ECM1 decreased sensitivity to GEM. We also assessed the clinicopathological significance of the expressions of ECM1 and KRT6A in 130 cases of PDAC. An immunohistochemical analysis showed that KRT6A expression dominated the poorly differentiated areas. High expressions of these two proteins in PDAC were associated with a poorer prognosis. Our results thus demonstrated that DEX treatment changed PDAC cells’ functions, resulting in decreased cell proliferation, increased cell migration and invasion, and decreased sensitivity to GEM. The molecular mechanisms of these changes involve ECM1 and KRT6A, whose expressions are induced by DEX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Pathology, Chiba University Hospital, Chiba, Japan.
- Division of Laboratory Medicine, Chiba University Hospital, Chiba, Japan.
- Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
ORCID-Profile: Yusuke Kouchi, Shigetsugu Takano, Takashi Kishimoto
Zitieren
APA
Shinomiya, Y., Kouchi, Y., Harada-Kagitani, S., Ishige, T., Takano, S., Ohtsuka, M., Ikeda, J. I., & Kishimoto, T. (2024). ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer. Cancer Science. https://doi.org/10.1111/cas.16175
Vancouver
Shinomiya Y, Kouchi Y, Harada-Kagitani S, Ishige T, Takano S, Ohtsuka M, et al. ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer. Cancer Science. 2024. doi:10.1111/cas.16175
BibTeX
@article{Shinomiya2024,
author = {Shinomiya, Yoshiki and Kouchi, Yusuke and Harada-Kagitani, Sakurako and Ishige, Takayuki and Takano, Shigetsugu and Ohtsuka, Masayuki and Ikeda, Jun-Ichiro and Kishimoto, Takashi},
title = {ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16175}
}
EUVIMED